Concepedia

Author

Shizuka Kaneko

Takatsuki Red Cross HospitalORCID

Also Known As

Akihiro Hamasaki, Nobuaki Watanabe, S Kaneko, S. KANEKO, SHIZUKA KANEKO, Satoshi Inoue, Shizuka Kaneko, Yuya Suzuki

48

Publications

2.4K

Citations

12

H-Index

18

Concepts

All Affiliations

Takatsuki Red Cross HospitalNovo Nordisk (Denmark)Kawasaki Medical SchoolKansai Electric Power HospitalKyoto University
SK

About

Shizuka Kaneko is an author at Takatsuki Red Cross Hospital specializing in medicine, diabetes, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

1.7K

2

Diabetes

4

4

1.7K

3

Gastroenterology

1

1

53

4

Immunology

1

1

53

5

Nephrology

1

1

589

Shizuka Kaneko

×

14

Publications

2.1K

Citations

12

H-Index

YearCitations

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

Julio Rosenstock, Carol Wysham, Juan P. Frías,

The Lancet

2021

907

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress,

The Lancet

2019

589

Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto,

The Lancet Diabetes & Endocrinology

2020

182

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp> apanese people with type 2 diabetes

Yutaka Seino, Yasuo Terauchi, Takeshi Osonoi,

Diabetes Obesity and Metabolism

2017

108

Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial

Shizuka Kaneko, Francis C. C. Chow, Dong Seop Choi,

Diabetes Research and Clinical Practice

2014

80

Combination therapy with liraglutide and insulin in Japanese patients with type 2 diabetes: A 36‐week, randomized, double‐blind, parallel‐group trial

Yutaka Seino, Shizuka Kaneko, Shuichi Fukuda,

Journal of Diabetes Investigation

2015

55

The vast majority of gastric T cells are polarized to produce T helper 1 type cytokines upon antigenic stimulation despite the absence of Helicobacter pylori infection

Toshiyuki Itoh, Yoshio Wakatsuki, Masaru Yoshida,

Journal of Gastroenterology

1999

53

GLP1 Receptor Agonist Liraglutide Is an Effective Therapeutic Option for Perioperative Glycemic Control in Type 2 Diabetes within Enhanced Recovery After Surgery (ERAS) Protocols

Shizuka Kaneko, Youhei Ueda, Yumiko Tahara

European Surgical Research

2018

28

Superior HbA1c control with the fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with a maximum dose of 50 units of insulin degludec in Japanese individuals with type 2 diabetes in a phase 3, double‐blind, randomized trial

Hirotaka Watada, Shizuka Kaneko, Mitsuhisa Komatsu,

Diabetes Obesity and Metabolism

2019

28

Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52‐week, open‐label, parallel‐group trial

Kohei Kaku, Arihiro Kiyosue, Yuri Ono,

Journal of Diabetes Investigation

2015

23

Page 1